Purple Biotech Announces Initiation of Part 2 of Ongoing Phase 1/2 Clinical Trial Evaluating NT219 for Treatment of Multiple Cancers Supporting Potential Expansion of Clinical Program
December 06, 2021 07:30 ET
|
Purple Biotech Ltd.
Part 2 is a Dose Escalation Study of NT219, in Combination with cetuximab (ERBITUX®), in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck Cancer or Colorectal...
Purple Biotech to Present at the Jefferies London Healthcare Conference
November 03, 2021 07:30 ET
|
Purple Biotech Ltd.
REHOVOT, Israel, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" ", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and...
Purple Biotech Expands Research Collaboration in Immuno-Oncology in Combination with NT219
October 26, 2021 08:27 ET
|
Purple Biotech Ltd.
Collaboration to Study NT219 in Combination with anti-CTLA4 and anti-PD1/PDL1 Antibodies REHOVOT, Israel, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the...
Purple Biotech Announces Publication in Nature Cancer Demonstrating Mechanisms Behind Cancer Cell Persistence Frequency and Potential of NT219 to Reduce Therapeutic Resistance
October 22, 2021 06:00 ET
|
Purple Biotech Ltd.
Research Highlights Underlying the IRS1 Phosphorylation Status as a Memory Mechanism that Modulates Cellular Non-Genetic Resistance to Drug Therapy NT219, which Targets IRS, Shown to be Highly...
Purple Biotech to Present Overview of Ongoing Phase 1b/2 Clinical Trial of CM24 for Treatment of Multiple Advanced Cancers at ESMO 2021 and Provides Clinical Update
September 13, 2021 07:00 ET
|
Purple Biotech Ltd.
One Advanced Pancreatic Cancer Patient Demonstrated a Partial Response in First Dose Cohort in Combination with Nivolumab Patient Enrollment in Second Dose Cohort Complete Study Expanding...
Purple Biotech Provides Corporate Update and Reports First Half 2021 Financial Results
August 05, 2021 08:30 ET
|
Purple Biotech Ltd.
REHOVOT, Israel, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech”, or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and...
Purple Biotech Presents New Clinical Data from NT219 at the 2021 ASCO Annual Meeting
June 04, 2021 08:00 ET
|
Purple Biotech Ltd.
Partial Response Observed in a Patient with Refractory Gastroesophageal Junction Cancer REHOVOT, Israel, June 04, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the...
Purple Biotech to Present at the Jefferies Virtual Healthcare Conference
May 26, 2021 07:38 ET
|
Purple Biotech Ltd.
REHOVOT, Israel, May 26, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and...
Purple Biotech to Present New Clinical Data from NT219 at the 2021 ASCO Annual Meeting
May 20, 2021 07:00 ET
|
Purple Biotech Ltd.
Initial Data from Ongoing Phase 1/2 Clinical Trial of NT219 in Adults with Advanced Solid Tumors and Head and Neck Cancer to be Highlighted REHOVOT, Israel, May 20, 2021 (GLOBE NEWSWIRE) -- ...
Purple Biotech Appoints Seasoned Biopharmaceutical Industry Executive Suzana Nahum-Zilberberg to Board of Directors
May 19, 2021 07:00 ET
|
Purple Biotech Ltd.
REHOVOT, Israel, May 19, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" ", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and...